Polymerase theta inhibition synergizes with anti-PD-1 immunotherapy in BRCA2-deficient pancreatic ductal adenocarcinoma.

被引：0
|
作者：
Patterson-Fortin, Jeffrey [1 ]
Jadhav, Heta [1 ]
Pantelidou, Constantia [2 ]
Phan, Tin [1 ]
Grochala, Carter [1 ]
Hao, Jie [1 ]
Wang, Junning [1 ]
Andrews, Elizabeth A. [1 ]
Guerriero, Jennifer L. [3 ]
Wolpin, Brian M. [1 ]
Stanger, Ben Z. [4 ]
Aguirre, Andrew A. [1 ]
Cleary, James M. [1 ]
D'Andrea, Alan A. [1 ]
Shapiro, Geoffrey I. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Bayer US LLC, Pharmaceut, Boston, MA USA
[3] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[4] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C010
引用
收藏
页码：117 / 118
页数：2
相关论文
共 50 条
  • [41] TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy
    Liu, Heng-Jia
    Lizotte, Patrick H.
    Du, Heng
    Speranza, Maria C.
    Lam, Hilaire C.
    Vaughan, Spencer
    Alesi, Nicola
    Wong, Kwok-Kin
    Freeman, Gordon J.
    Sharpe, Arlene H.
    Henske, Elizabeth P.
    JCI INSIGHT, 2018, 3 (08):
  • [42] Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors
    Matos, Ana I. I.
    Peres, Carina
    Carreira, Barbara
    Moura, Liane I. F.
    Acurcio, Rita C. C.
    Vogel, Theresa
    Wegener, Erik
    Ribeiro, Filipa
    Afonso, Marta B. B.
    Santos, Fabio M. F.
    Martinez-Barriocanal, Agueda
    Arango, Diego
    Viana, Ana S. S.
    Gois, Pedro M. P.
    Silva, Liana C. C.
    Rodrigues, Cecilia M. P.
    Graca, Luis
    Jordan, Rainer
    Satchi-Fainaro, Ronit
    Florindo, Helena F. F.
    ADVANCED SCIENCE, 2023, 10 (25)
  • [43] Immunotherapy engagement in pancreatic adenocarcinoma: Provisional results of iLSTA study- Durvalumab, LSTA1 (certepetide), gemcitabine, and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma.
    Dean, Andrew Peter
    Johansson, Mikael
    Yusoff, Ian
    Rao, Samarth
    Sparrow, Susan
    Kumarasinghe, Priyanthi
    Navadgi, Suresh
    Watanabe, Yuki
    Webber, Laurence
    Grew, Jenny
    Fitzgerald, Shane
    Comito, Olivia Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [44] Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic cancer
    Xun, Jing
    Jiang, Xiaolin
    Liu, Bin
    Hu, Zhibo
    Liu, Jinjin
    Han, Yingdi
    Gao, Ruifang
    Zhang, Hui
    Yang, Shimin
    Yu, Xiangyang
    Wang, Ximo
    Yan, Chen
    Zhang, Qi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 139
  • [45] Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experimental study
    Zhang, Haoxiang
    Chen, Jiaoshun
    Bai, Jianwei
    Zhang, Jing
    Huang, Shaoyi
    Zeng, Liang
    Zhou, Pengfei
    Shen, Qiang
    Yin, Tao
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (05) : 2679 - 2691
  • [46] Inhibition potentiates immunogenicity in Merkel cell carcinoma: a promising approach to overcome resistance to anti-PD-1 immunotherapy
    Bhakuni, Rashmi
    Goff, Peter H.
    Lee, Jung Hyun
    Pulliam, Thomas
    Tabachnick-Cherny, Shira
    Morningstar, Carina D.
    Nghiem, Paul
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (10) : 2837 - 2837
  • [47] SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy
    Wang, Peng
    Qiu, Jiannan
    Fang, Yuan
    Li, Songmao
    Liu, Kua
    Cao, Yin
    Zhang, Guang
    Wang, Zhongxia
    Gu, Xiaosong
    Wu, Junhua
    Jiang, Chunping
    CELL DEATH AND DIFFERENTIATION, 2025,
  • [48] Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma
    Zhou, Min
    Zhang, Xiuxiu
    Li, Tianyang
    Chen, Yan
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (12)
  • [49] Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy
    Noman, Muhammad Zaeem
    Parpal, Santiago
    Van Moer, Kris
    Xiao, Malina
    Yu, Yasmin
    Viklund, Jenny
    De Milito, Angelo
    Hasmim, Meriem
    Andersson, Martin
    Amaravadi, Ravi K.
    Martinsson, Jessica
    Berchem, Guy
    Janji, Bassam
    SCIENCE ADVANCES, 2020, 6 (18)
  • [50] CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy
    Pant, Ayush
    Bergsneider, Brandon Hwa-Lin
    Srivastava, Siddhartha
    Kim, Timothy
    Jain, Aanchal
    Bom, Sadhana
    Shah, Pavan
    Kannapadi, Nivedha
    Patel, Kisha
    Choi, John
    Cho, Kwang Bog
    Verma, Rohit
    Wu, Caren Yu-Ju
    Brem, Henry
    Tyler, Betty
    Pardoll, Drew M.
    Jackson, Christina
    Lim, Michael
    ONCOIMMUNOLOGY, 2024, 13 (01):
12345